• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Liquid biopsies come of age in lung cancer.

作者信息

Christopoulos Petros

机构信息

Department of Medical Oncology, Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital, Heidelberg, Germany.

Translational Lung Research Center at Heidelberg University Hospital, The German Center for Lung Research (DZL), Heidelberg, Germany.

出版信息

Transl Lung Cancer Res. 2022 May;11(5):706-710. doi: 10.21037/tlcr-22-268.

DOI:10.21037/tlcr-22-268
PMID:35693286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9186179/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/606b/9186179/49371162f8ad/tlcr-11-05-706-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/606b/9186179/49371162f8ad/tlcr-11-05-706-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/606b/9186179/49371162f8ad/tlcr-11-05-706-f1.jpg

相似文献

1
Liquid biopsies come of age in lung cancer.液体活检在肺癌领域已走向成熟。
Transl Lung Cancer Res. 2022 May;11(5):706-710. doi: 10.21037/tlcr-22-268.
2
The Present and Future of Liquid Biopsies in Non-Small Cell Lung Cancer: Combining Four Biosources for Diagnosis, Prognosis, Prediction, and Disease Monitoring.液体活检在非小细胞肺癌中的现状与未来：联合四种生物源进行诊断、预后、预测和疾病监测。
Curr Oncol Rep. 2018 Jul 20;20(9):70. doi: 10.1007/s11912-018-0720-z.
3
Liquid biopsies in lung cancer-time to implement research technologies in routine care?肺癌中的液体活检——是时候将研究技术应用于常规护理了吗？
Ann Transl Med. 2017 Jul;5(13):278. doi: 10.21037/atm.2017.04.12.
4
Liquid Biopsies in a Veteran Patient Population With Advanced Prostate and Lung Non-Small Cell Carcinomas: A New Paradigm and Unique Challenge in Personalized Medicine.老年前列腺癌和肺非小细胞癌患者群体中的液体活检：个性化医疗的新范式与独特挑战
Fed Pract. 2021 Jan;38(1):8-14. doi: 10.12788/fp.0065.
5
A liquid biopsy in primary lung cancer.原发性肺癌的液体活检
Surg Today. 2019 Jan;49(1):1-14. doi: 10.1007/s00595-018-1659-2. Epub 2018 Apr 11.
6
Shallow whole-genome sequencing of plasma cell-free DNA accurately differentiates small from non-small cell lung carcinoma.血浆游离 DNA 浅层全基因组测序能准确区分小细胞肺癌和非小细胞肺癌。
Genome Med. 2020 Apr 21;12(1):35. doi: 10.1186/s13073-020-00735-4.
7
Clinical applications of liquid biopsies for early lung cancer detection.液体活检在早期肺癌检测中的临床应用。
Am J Cancer Res. 2019 Dec 1;9(12):2567-2579. eCollection 2019.
8
Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform.使用GeneReader二代测序平台对晚期非小细胞肺癌患者进展至靶向治疗后进行液体活检的前瞻性分析。
Transl Cancer Res. 2019 Jan;8(Suppl 1):S3-S15. doi: 10.21037/tcr.2018.10.12.
9
Liquid Biopsies in Lung Cancer: Four Emerging Technologies and Potential Clinical Applications.肺癌中的液体活检：四种新兴技术及潜在临床应用
Cancers (Basel). 2019 Mar 7;11(3):331. doi: 10.3390/cancers11030331.
10
Molecular profile of liquid biopsies: next generation biomarkers to improve lung cancer treatment.液体活检的分子特征：改善肺癌治疗的新一代生物标志物
Ecancermedicalscience. 2015 Nov 24;9:598. doi: 10.3332/ecancer.2015.598. eCollection 2015.

引用本文的文献

1
A new reality of molecular surveillance for resected lung cancer.切除性肺癌分子监测的新现状
Transl Lung Cancer Res. 2025 Jul 31;14(7):2369-2373. doi: 10.21037/tlcr-2025-523. Epub 2025 Jul 17.
2
Values of circulating tumor DNA for non-small cell lung cancer patients receiving neoadjuvant therapy, progress and challenges: a narrative review.接受新辅助治疗的非小细胞肺癌患者循环肿瘤DNA的价值、进展与挑战：一项叙述性综述
J Thorac Dis. 2024 Jul 30;16(7):4742-4755. doi: 10.21037/jtd-24-265. Epub 2024 Jul 4.
3
An advanced NSCLC patient with and fusions treated with -TKI combination therapy: a case report.

本文引用的文献

1
Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer.使用Oncomine Precision Assay与Genexus™集成测序仪对非小细胞肺癌中的循环肿瘤DNA进行快速基因组分析。
Transl Lung Cancer Res. 2022 May;11(5):711-721. doi: 10.21037/tlcr-21-981.
2
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab.个性化循环肿瘤DNA分析作为帕博利珠单抗治疗实体瘤患者的预测生物标志物
Nat Cancer. 2020 Sep;1(9):873-881. doi: 10.1038/s43018-020-0096-5. Epub 2020 Aug 3.
3
Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications.
一名接受-TKI联合治疗的伴有和融合的晚期非小细胞肺癌患者：病例报告。 你提供的原文中“with and fusions”部分内容缺失，请补充完整准确信息以便能有更精准的翻译。
Transl Lung Cancer Res. 2023 Dec 26;12(12):2538-2549. doi: 10.21037/tlcr-23-656. Epub 2023 Nov 24.
4
Editorial: Systemic immune dysregulation in malignant disease: Insights, monitoring and therapeutic exploitation.社论：恶性疾病中的全身免疫失调：见解、监测与治疗应用
Front Oncol. 2023 Apr 3;13:1182081. doi: 10.3389/fonc.2023.1182081. eCollection 2023.
5
Gene expression profiling of circulating tumor cells captured by MicroCavity Array is superior to enumeration in demonstrating therapy response in patients with newly diagnosed advanced and locally advanced non-small cell lung cancer.微腔阵列捕获的循环肿瘤细胞的基因表达谱分析在证明新诊断的晚期和局部晚期非小细胞肺癌患者的治疗反应方面优于计数。
Transl Lung Cancer Res. 2023 Jan 31;12(1):109-126. doi: 10.21037/tlcr-22-314. Epub 2023 Jan 16.
融合阳性非小细胞肺癌：生物学原理、临床实践和诊断意义。
Genes Chromosomes Cancer. 2022 May;61(5):244-260. doi: 10.1002/gcc.23022. Epub 2022 Jan 22.
4
Early identification of disease progression in ALK-rearranged lung cancer using circulating tumor DNA analysis.使用循环肿瘤DNA分析早期识别ALK重排肺癌的疾病进展
NPJ Precis Oncol. 2021 Dec 7;5(1):100. doi: 10.1038/s41698-021-00239-3.
5
Liquid Biopsies beyond Mutation Calling: Genomic and Epigenomic Features of Cell-Free DNA in Cancer.超越突变检测的液体活检：癌症中游离DNA的基因组和表观基因组特征
Cancers (Basel). 2021 Nov 10;13(22):5615. doi: 10.3390/cancers13225615.
6
Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.循环肿瘤 DNA 动态预测局部晚期非小细胞肺癌巩固免疫治疗的获益。
Nat Cancer. 2020 Feb;1(2):176-183. doi: 10.1038/s43018-019-0011-0. Epub 2020 Jan 20.
7
Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer.表皮生长因子受体（EGFR）突变型肺癌序贯靶向治疗的真实世界应用
Ther Adv Med Oncol. 2021 Mar 24;13:1758835921996509. doi: 10.1177/1758835921996509. eCollection 2021.
8
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer.液体活检在晚期 NSCLC 中的应用：国际肺癌研究协会的共识声明。
J Thorac Oncol. 2021 Oct;16(10):1647-1662. doi: 10.1016/j.jtho.2021.06.017. Epub 2021 Jul 8.
9
Earlier extracranial progression and shorter survival in ALK-rearranged lung cancer with positive liquid rebiopsies.液体活检呈阳性的ALK重排肺癌患者出现更早的颅外进展且生存期更短。
Transl Lung Cancer Res. 2021 May;10(5):2118-2131. doi: 10.21037/tlcr-21-32.
10
Feasibility and Challenges for Sequential Treatments in ALK-Rearranged Non-Small-Cell Lung Cancer.ALK重排非小细胞肺癌序贯治疗的可行性与挑战
Front Oncol. 2021 Apr 20;11:670483. doi: 10.3389/fonc.2021.670483. eCollection 2021.